DIVI S LABORATORIES LTD Fair Value
DIVISLAB · Healthcare · Current price ₹9,140
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹774 | 17% ROE fading to 12% over ~10 yrs, on ₹631 book |
| Relative P/E | ₹3,783 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹1,172 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹8,332 | Street consensus 12-month target price |
Is DIVI S LABORATORIES LTD undervalued?
DocStoX estimates the fair value of DIVI S LABORATORIES LTD at ₹2,876 per share, versus the current market price of ₹9,140. That puts the stock about -68.5% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹774), Relative P/E (₹3,783), Graham floor (₹1,172), Analyst target (₹8,332). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹774 (bear) to ₹2,876 (base) to ₹8,332 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on DIVI S LABORATORIES LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.